Biodesix Inc
BDSX0.296USD
-0.004-1.46%
Close 06/04, 16:00（ET）Quotes delayed by 15 min
43.38MMarket Cap
LossP/E TTM
More Details of Biodesix Inc Company
Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
Company Info
Company codeBDSX
Company nameBiodesix Inc
IPO dateOct 28, 2020
Founded at2005
CEOMr. Scott Hutton
Number of employees273
Security typeOrdinary Share
Fiscal year-endOct 28
Address919 West Dillon Road
CityLOUISVILLE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code80027
Phone13034170500
Websitehttps://www.biodesix.com/
Company codeBDSX
IPO dateOct 28, 2020
Founded at2005
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. John Patience
Mr. John Patience
Independent Chairman of the Board
Independent Chairman of the Board
7.42M
+1.26%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
3.06M
--
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
357.54K
--
Mr. Hany Massarany
Mr. Hany Massarany
Independent Director
Independent Director
337.13K
+0.81%
Ms. Robin Harper Cowie
Ms. Robin Harper Cowie
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
248.63K
+0.88%
Mr. Kieran O'Kane
Mr. Kieran O'Kane
Chief Commercial Officer
Chief Commercial Officer
139.05K
+0.73%
Ms. Jean M. Franchi, CPA
Ms. Jean M. Franchi, CPA
Independent Director
Independent Director
108.14K
+32.25%
Mr. Lawrence T. (Lair) Kennedy, Jr.
Mr. Lawrence T. (Lair) Kennedy, Jr.
Independent Director
Independent Director
--
--
Mr. Scott Hutton
Mr. Scott Hutton
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John Patience
Mr. John Patience
Independent Chairman of the Board
Independent Chairman of the Board
7.42M
+1.26%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
3.06M
--
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
357.54K
--
Mr. Hany Massarany
Mr. Hany Massarany
Independent Director
Independent Director
337.13K
+0.81%
Ms. Robin Harper Cowie
Ms. Robin Harper Cowie
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
248.63K
+0.88%
Mr. Kieran O'Kane
Mr. Kieran O'Kane
Chief Commercial Officer
Chief Commercial Officer
139.05K
+0.73%
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
By BusinessUSD
Name
Revenue
Proportion
Lung Diagnostic Testing
64.71M
90.73%
Development Services
6.62M
9.27%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Lung Diagnostic Testing
64.71M
90.73%
Development Services
6.62M
9.27%
Shareholder
Update time: Thu, May 15
Update time: Thu, May 15
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Schuler (Jack W)
24.51%
Kennedy (Lawrence T Jr.)
17.37%
Telemark Asset Management, LLC
5.65%
Patience (John)
5.07%
Bryn Mawr Trust Company
4.16%
Other
43.25%
Shareholder Statistics
Shareholder
Proportion
Schuler (Jack W)
24.51%
Kennedy (Lawrence T Jr.)
17.37%
Telemark Asset Management, LLC
5.65%
Patience (John)
5.07%
Bryn Mawr Trust Company
4.16%
Other
43.25%
Type
Shareholder
Proportion
Individual Investor
50.74%
Investment Advisor
11.75%
Hedge Fund
9.83%
Investment Advisor/Hedge Fund
6.18%
Bank and Trust
4.16%
Private Equity
3.67%
Corporation
1.49%
Research Firm
0.79%
Venture Capital
0.07%
Other
11.32%
Institutional Shareholding
Update time: Sat, Feb 22
Update time: Sat, Feb 22
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
114
128.07M
87.48%
-971.92K
2024Q4
117
129.55M
88.77%
+1.50M
2024Q3
108
133.06M
91.48%
+18.48M
2024Q2
113
122.73M
87.79%
+36.49M
2024Q1
129
78.49M
81.85%
-3.28M
2023Q4
126
82.91M
102.14%
+18.03M
2023Q3
132
83.04M
103.87%
+18.19M
2023Q2
137
65.80M
84.63%
+503.77K
2023Q1
140
65.48M
84.42%
+858.57K
2022Q4
144
63.63M
87.33%
+26.33M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Schuler (Jack W)
30.79M
21.1%
+86.96K
+0.28%
May 23, 2024
Kennedy (Lawrence T Jr.)
25.35M
17.36%
+4.35M
+20.70%
May 21, 2024
Telemark Asset Management, LLC
8.28M
5.67%
--
--
Dec 31, 2024
Patience (John)
7.38M
5.05%
+46.69K
+0.64%
Mar 31, 2025
Bryn Mawr Trust Company
6.10M
4.18%
--
--
Dec 31, 2024
Birchview Capital, LP
5.58M
3.82%
+40.00K
+0.72%
Dec 31, 2024
SilverArc Capital Management, LLC
4.33M
2.97%
+771.19K
+21.66%
Dec 31, 2024
Monashee Investment Management, LLC
3.50M
2.4%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
3.82M
2.62%
+861.00K
+29.06%
Dec 31, 2024
Opaleye Management Inc.
3.46M
2.37%
-350.00K
-9.17%
Dec 31, 2024
View more
Related ETFs
Update time: Mon, Jun 2
Update time: Mon, Jun 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
